---
input_text: 'CRISPR/dCas9 as a Therapeutic Approach for Neurodevelopmental Disorders:
  Innovations and Limitations Compared to Traditional Strategies. Brain development
  is a complex process that requires a series of precise and coordinated events to
  take place. When alterations in some of those events occur, neurodevelopmental disorders
  (NDDs) may appear, with their characteristic symptoms, including cognitive, social
  motor deficits, and epilepsy. While pharmacologic treatments have been the only
  therapeutic options for many years, more recently the research is turning to the
  direct removal of the underlying genetic cause of each specific NDD. This is possible
  thanks to the increased knowledge of genetic basis of those diseases and the enormous
  advances in genome-editing tools. Together with clustered regularly interspaced
  short palindromic repeats (CRISPR)/Cas9-based strategies, there is a great development
  also of nuclease defective Cas9 (dCas9) tools that, with an extreme flexibility,
  allow the recruitment of specific protein functions to the desired genomic sites.
  In this work, we review dCas9-based tools and discuss all the published applications
  in the setting of therapeutic approaches for NDDs at the preclinical level. In particular,
  dCas9-based therapeutic strategies for Dravet syndrome, transcallosal dysconnectivity
  caused by mutations in C11orf46 gene, and Fragile X syndrome are presented and discussed.
  A direct comparison with other possible therapeutic strategies, such as classic
  gene replacement or CRISPR/Cas9-based strategies, is provided. We also highlight
  not only those aspects that constitute a clear advantage compared to previous strategies
  but also the main technical hurdles related to their applications that need to be
  overcome.'
raw_completion_output: |-
  primary_disease: Neurodevelopmental disorders (NDDs)

  medical_actions: Pharmacologic treatments;Direct removal of the underlying genetic cause;CRISPR/Cas9-based strategies;dCas9-based tools

  symptoms: Cognitive deficits;Social motor deficits;Epilepsy

  chemicals: 

  action_annotation_relationships: Pharmacologic treatments TREATS Cognitive deficits IN Neurodevelopmental disorders;Pharmacologic treatments TREATS Social motor deficits IN Neurodevelopmental disorders;Pharmacologic treatments TREATS Epilepsy IN Neurodevelopmental disorders;Direct removal of the underlying genetic cause PREVENTS Cognitive deficits IN Neurodevelopmental disorders;Direct removal of the underlying genetic cause PREVENTS Social motor deficits IN Neurodevelopmental disorders;Direct removal of the underlying genetic cause PREVENTS Epilepsy IN Neurodevelopmental disorders;CRISPR/Cas9-based strategies TREATS Cognitive deficits IN Neurodevelopmental disorders;CRISPR/Cas9-based strategies TREATS Social motor deficits IN Neurodevelopmental disorders;CRISPR/Cas9-based strategies TREATS Epilepsy IN Neurodevelopmental disorders;dCas9-based tools TREATS Cognitive deficits IN Neurodevelopmental disorders;dCas9-based tools TREATS Social motor deficits IN Neurodevelopmental disorders;dCas9-based tools TREATS Epilepsy IN Neurodevelopmental disorders
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  dCas9-based tools TREATS Epilepsy IN Neurodevelopmental disorders

  ===

extracted_object:
  primary_disease: MONDO:0700092
  medical_actions:
    - Pharmacologic treatments
    - Direct removal of the underlying genetic cause
    - CRISPR/Cas9-based strategies
    - dCas9-based tools
  symptoms:
    - HP:0100543
    - Social motor deficits
    - HP:0001250
  action_annotation_relationships:
    - subject: Pharmacologic treatments
      predicate: TREATS
      object: HP:0100543
      qualifier: MONDO:0700092
    - subject: Pharmacologic treatments
      predicate: TREATS
      object: Social motor deficits
      qualifier: MONDO:0700092
      subject_extension: Pharmacologic treatments
      object_extension: Social motor deficits
    - subject: Pharmacologic treatments
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0700092
      subject_extension: Pharmacologic treatments
    - subject: Direct removal of the underlying genetic cause
      predicate: PREVENTS
      object: HP:0100543
      qualifier: MONDO:0700092
    - subject: <Direct removal of the underlying genetic cause>
      predicate: <PREVENTS>
      object: <Social motor deficits>
      qualifier: <Neurodevelopmental disorders>
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - subject: <Direct removal of the underlying genetic cause>
      predicate: <PREVENTS>
      object: <Epilepsy>
      qualifier: <Neurodevelopmental disorders>
      subject_qualifier: <NA>
      object_qualifier: <NA>
      subject_extension: <NA>
      object_extension: <NA>
    - subject: CRISPR/Cas9-based strategies
      predicate: TREATS
      object: HP:0100543
      qualifier: MONDO:0700092
      subject_extension: CRISPR/Cas9-based strategies
    - subject: CRISPR/Cas9-based strategies
      predicate: TREATS
      object: Social motor deficits
      qualifier: MONDO:0700092
      subject_extension: CRISPR/Cas9-based strategies
    - subject: CRISPR/Cas9-based strategies
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0700092
      subject_extension: CRISPR/Cas9-based strategies
    - subject: dCas9-based tools
      predicate: TREATS
      object: HP:0100543
      qualifier: MONDO:0700092
      subject_extension: dCas9-based tools
    - subject: dCas9-based tools
      predicate: TREATS
      object: Social motor deficits
      qualifier: MONDO:0700092
      subject_extension: dCas9-based tools
    - subject: dCas9-based tools
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0700092
      subject_extension: dCas9-based tools
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
